Enhanced Genomics, a UK-based drug discovery firm utilizing a 3D multiomics platform called GenLink, raised an extended Series A funding round totaling $19 million. The capital will support expansion into autoimmune disease targets like inflammatory bowel disease and strengthen strategic partnerships with pharmaceutical and biotech companies to advance genetically validated drug candidates.